• Explore /
  • Poster
  • / Investigation of metformin (MET) in patients with castration resistant prostate cancer (CRPC) in combination with enzalutamide (ENZ) vs. ENZ alone: A randomized, open label, phase 2 trial. SAKK 08/14—IMPROVE.

Investigation of metformin (MET) in patients with castration resistant prostate cancer (CRPC) in combination with enzalutamide (ENZ) vs. ENZ alone: A randomized, open label, phase 2 trial. SAKK 08/14—IMPROVE.

Abstract Poster

Authors

null

Christian Alexander Rothermundt

Kantonsspital St Gallen, St Gallen, Switzerland

Christian Alexander Rothermundt , Richard Cathomas , Alexandros Xyrafas , Martina Schneider , Christine Biaggi Rudolf , Enrico Roggero , Natalie Fischer , Sacha Rothschild , Anna Patrikidou , Walter B. Mingrone , Thomas Hermanns , Tobias Wehrhahn , Andreas Erdmann , Beat Mueller , Pierre Oliver Bohanes , Karin Ribi , Silke Gillessen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02640534

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS5086)

DOI

10.1200/JCO.2018.36.15_suppl.TPS5086

Abstract #

TPS5086

Poster Bd #

313a

Abstract Disclosures

Similar Posters

First Author: Mamta Parikh

First Author: Fernando C. Maluf

First Author: Xiao X. Wei

First Author: Sumit Kumar Subudhi